Benefix Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to hemophilia b disease burden, plasma safety concerns, early recombinant factor adoption, frequent bleeding episodes, specialized treatment center growth.

The growth in the forecast period can be attributed to increasing prophylaxis uptake, improved recombinant manufacturing, pediatric patient adoption, enhanced homecare support, broader treatment access programs. Major trends in the forecast period include shift toward recombinant factor ix therapies, expansion of prophylactic hemophilia management, reduced dependence on plasma derived factors, improved home based bleeding management, rising adoption of routine preventive dosing.

The rising prevalence of hemophilia is expected to drive the growth of the benefix market in the coming years. Hemophilia is a chronic bleeding disorder that requires long-term management, and increasing healthcare expenditure reflects the growing demand for treatments for such conditions. Benefix aids in effective hemophilia management by providing recombinant factor IX therapy, suitable for patients with factor IX deficiency. It enhances treatment reliability by preventing and controlling bleeding episodes quickly, improving patient safety and overall quality of life. For example, in July 2025, the National Blood Authority, an Australia-based blood management agency, reported 2,788 patients living with hereditary hemophilia A (HMA) in 2023-2024, up from 2,681 patients in 2022-2023. Therefore, the growing prevalence of hemophilia is supporting the expansion of the benefix market.

The rising healthcare expenditure is expected to further propel the growth of the benefix market. Healthcare expenditure refers to the total spending on health services, products, and infrastructure within a specific period, typically measured annually. The increase in healthcare spending is driven by factors such as an aging population, chronic diseases, higher service costs, technological advancements, rising drug prices, the COVID-19 impact, medical inflation, and income disparities. Higher healthcare expenditure enhances Benefix utilization by improving access to advanced recombinant factor IX therapies, making them more widely available for hemophilia B patients. It also supports better treatment outcomes by enabling investments in high-quality biologics, improving bleeding control and overall patient care. For instance, in 2023, the Centers for Medicare & Medicaid Services (CMS), a U.S.-based government agency, reported that U.S. healthcare spending rose by 7.5% to $4.9 trillion, up from $4.5 trillion in 2022. Therefore, rising healthcare expenditure is driving the growth of the Benefix market.

A growing focus on rare diseases is expected to support the growth of the benefix market. Rare diseases affect a small percentage of the population, typically fewer than 1 in 2,000 individuals. Increased attention on rare diseases is driven by advances in medical research, improved diagnostic technologies, and greater patient advocacy, leading to more awareness and development of targeted treatments. Benefix provides an effective solution for hemophilia B, a rare genetic bleeding disorder, by offering a consistent clotting therapy that minimizes the need for frequent infusions and improves quality of life for patients. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based nonprofit organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, a substantial increase from 6 approvals in 2022. Therefore, the growing focus on rare diseases is driving the benefix market.

Major companies operating in the benefix market are Pfizer Inc.

Asia-Pacific was the largest region in the benefix market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the benefix market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the benefix market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the benefix market by increasing costs for recombinant protein production inputs, sterile formulation materials, and cold chain logistics. These impacts affect hospital and homecare distribution channels. North america and europe experience pricing sensitivity due to biologic import reliance. However, tariffs are encouraging localized recombinant factor manufacturing. This improves long-term availability and cost control.

The benefix market research report is one of a series of new reports that provides benefix market statistics, including benefix industry global market size, regional shares, competitors with a benefix market share, detailed benefix market segments, market trends and opportunities, and any further data you may need to thrive in the benefix industry. This benefix market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Benefix is a recombinant coagulation factor IX product developed to treat and manage bleeding disorders resulting from factor IX deficiency, such as hemophilia B. It is used to prevent and control bleeding episodes, manage perioperative bleeding, and reduce the frequency of spontaneous bleeding in hemophilia B patients through routine prophylaxis.

The primary clinical indications for benefix include hemophilia B and surgical prophylaxis. Hemophilia B is a rare genetic bleeding disorder caused by a deficiency of clotting factor IX, resulting in prolonged or spontaneous bleeding episodes. Benefix is used in hospitals, clinics, and homecare settings and is distributed through direct sales, retail pharmacies, and online pharmacies.

The benefix market consists of sales of products such as single-use vials, alprolix, beneFix+, and xyntha. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.